Antibiotic R&D has had a particularly bad year starting with The Medicines Company who abandoned their antibiotic R&D efforts and sold their antibiotic assets to Melinta late last year right after getting approval for vabomere. This year both Sanofi and Novartis abandoned their antibiotic R&D efforts and divested their clinical and preclinical assets. Allergan, holder of the North American rights to ceftaroline, dalbavancin and ceftazidime-avibactam, also announced that they would divest their antibiotic assets. I have not heard that they were successful. Achaogen has now undergone two efforts at “restructuring” involving virtually eliminating all R&D and has essentially put up the “for sale” sign just after achieving approval for plazomicin. Finally, Melinta abandoned their antibiotic R&D efforts in the face of miserable sales of their recently launched antibiotics including delafloxacin and vabomere.
Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead of the game.
External innovations come in different forms and originate in different places -- from university labs, to privately held venture capital-backed startups and contract research organizations (CROs). Let’s get to reviewing some of the most influential research trends which will be “hot” in 2018 and beyond, and summarize some of the key players driving innovations.
Evaxion Biotech uses its machine learning-based platform to compare DNAs of tumor cells and DNAs healthy cells and identify mutations that are critical for the disease. This data is further used to design anticancer vaccines.
Pharmaceutical industry is rapidly evolving, influenced by emerging novel technologies and recent advances in Life Sciences and Big Data analysis, new government policies and regulations, and a changing market conjuncture.
Let’s review some of the most powerful trends that will dominate the industry in 2017 and promising biopharmaceutical startups riding their waves.
To date, nature has been the best teacher for drug discovery scientists, especially for those who develop antimicrobial drugs. Lately, a new example proving this notion emerged in press - a recent publication in a prestigious research journal Nature describing a new powerful method of identifying yet unknown classes of antibiotics by learning from bacteria living in our body - microbiota.